Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Innovative Technology to Change Current Standard of Care for Bladder Cancer Patients

• The company’s proprietary technology could change the way surgeons handle cystoscopy procedures by displaying white light and blue light images side-by-side on one screen
• The technology is primarily promoted as an imaging device for bladder cancer but has the potential to expand to other endoscopic procedures including laparoscopic, colorectal and thoracic
• Bladder cancer is the sixth most prevalent cancer in the United States, with 600,000 people fearing recurrence
• The global market for bladder cancer is estimated to grow to an estimated $4.71 billion by 2026

The current standard of care for bladder cancer is minimally invasive surgery (MIS)uses white light to illuminate the cancer in the bladder. The 30-year-old white light method is highly effective for visualizing the cancerous tumors that protrude above the bladder’s wall. Unfortunately, it is difficult to distinguish flat tumors from normal tissue and the margins of the tumor are almost impossible to visualize with the current standards.

The introduction of blue light in combination with a fluorescent contrasting druglight has been a game-changer in the industry, with one major exception – it cannot be used in real-time. Surgeons are required to flip between the white light and…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.